Winston Medical Supply Past Earnings Performance
Past criteria checks 6/6
Winston Medical Supply has been growing earnings at an average annual rate of 38.1%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 13.6% per year. Winston Medical Supply's return on equity is 37.1%, and it has net margins of 22.4%.
Key information
38.1%
Earnings growth rate
37.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 13.6% |
| Return on equity | 37.1% |
| Net Margin | 22.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Winston Medical Supply makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 709 | 159 | 143 | 9 |
| 30 Sep 23 | 686 | 150 | 138 | 8 |
| 30 Jun 23 | 664 | 142 | 134 | 8 |
| 31 Mar 23 | 635 | 127 | 128 | 7 |
| 31 Dec 22 | 607 | 111 | 122 | 7 |
| 30 Sep 22 | 560 | 92 | 116 | 7 |
| 30 Jun 22 | 514 | 72 | 110 | 8 |
| 31 Mar 22 | 525 | 82 | 112 | 8 |
| 31 Dec 21 | 537 | 92 | 114 | 8 |
| 30 Sep 21 | 562 | 118 | 119 | 7 |
| 30 Jun 21 | 587 | 144 | 125 | 7 |
| 31 Mar 21 | 546 | 122 | 119 | 7 |
| 31 Dec 20 | 505 | 100 | 114 | 6 |
| 30 Sep 20 | 456 | 56 | 109 | 8 |
| 30 Jun 20 | 406 | 13 | 105 | 9 |
| 31 Mar 20 | 386 | 2 | 102 | 11 |
| 31 Dec 19 | 365 | -9 | 99 | 12 |
| 31 Dec 18 | 342 | -30 | 98 | 12 |
| 31 Dec 17 | 340 | -5 | 93 | 12 |
Quality Earnings: 6817 has high quality earnings.
Growing Profit Margin: 6817's current net profit margins (22.4%) are higher than last year (18.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6817 has become profitable over the past 5 years, growing earnings by 38.1% per year.
Accelerating Growth: 6817's earnings growth over the past year (42.7%) exceeds its 5-year average (38.1% per year).
Earnings vs Industry: 6817 earnings growth over the past year (42.7%) exceeded the Pharmaceuticals industry -15%.
Return on Equity
High ROE: 6817's Return on Equity (37.1%) is considered high.